Product logins

Find logins to all Clarivate products below.


Biosimilars | Current Treatment | Nephrology | US/EU | 2020

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in the United States in November 2018. Despite the availability of multiple ESA biosimilars for chronic kidney disease (CKD) for several years, their uptake in Europe has varied from country to country, as well as by drug and manufacturer. With new biosimilars expected to soon enter all three markets under study (United States, France, and Germany), it is vital to understand why ESA biosimilar uptake varies in Europe and the likely impact of upcoming biosimilar launches in the United States and Europe. We surveyed nephrologists from France, Germany, and the United States to learn about their experience and familiarity with current biosimilars, the drivers of and barriers to these agents’ uptake, nephrologists’ interest in prescribing biosimilars in the future, and their expectations for novel biosimilars.

Scope:

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 90 nephrologists.

Questions answered:

  • What is the current patient share of CKD biosimilars, and what expectations do nephrologists have for future patient shares?
  • How similar do nephrologists believe biosimilars are to their reference brands?
  • What factors do nephrologists identify as being the key drivers of and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to earn more than a 50% patient share?

Key companies mentioned:

  • Amgen
  • Janssen
  • Johnson & Johnson
  • Medice Arzneimittel Putter
  • Pfizer
  • Roche
  • Sandoz (Novartis)
  • Stada Arzneimittel
  • Vifor Pharma

Key drugs mentioned:

  • Abseamed
  • Aranesp
  • Binocrit
  • Epoetin Alfa Hexal
  • Epogen
  • Eprex/Erypro
  • Mircera
  • NeoRecormon
  • Procrit
  • Retacrit
  • Silapo

Related Market Assessment Reports

Report
Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)
Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…